The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

Methods are disclosed of designing antibodies for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,000. The method comprises preparing a first antibody that binds to the small molecule, and preparing a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a predetermined portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.

Provided is a compound of Chemical Formula 1: ##STR00001## wherein: X.sub.1 to X.sub.3 are each independently N or CH, provided that at least two of X.sub.1 to X.sub.3 are N, Y is O or S, L.sub.1 and L.sub.2 are each independently a single bond, or a substituted or unsubstituted C.sub.6-60 arylene or C.sub.2-60 heteroarylene containing one or more of O, N, Si, or S, and A is Chemical Formula 2 or 3, ##STR00002## each Z is independently CR, or two adjacent Zs are C each linked to the following Chemical Formula 4 at * to form a fused ring, and the rest are each independently CR: ##STR00003## T is O, S, CQ.sub.1Q.sub.2, or NAr.sub.4, and Ar.sub.1 to Ar.sub.4 are each independently a substituted or unsubstituted C.sub.6-60 aryl or C.sub.2-60 heteroaryl containing one or more of N, O, or S,
and an organic light emitting device including the same.

This application relates to compounds of Formula (I): ##STR00001##
or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

The present disclosure provides a compound configured to release nitric oxide (NO) and inhibit the activity of a phosphodiesterase (PDE) when administered to a subject. The compound may include L.sub.1 and L.sub.2. L.sub.1 may include a functional group that is part or all of a NO releasing agent. L.sub.2 may include a functional group that is part or all of a PDE inhibitor. The compound may further include a bond or a biradical that connects L.sub.1 and L.sub.2. The present disclosure further provides a method of treating or preventing a disease using the compound or a composition including the compound.

The present disclosure provides a compound configured to release nitric oxide (NO) and inhibit the activity of a phosphodiesterase (PDE) when administered to a subject. The compound may include L.sub.1 and L.sub.2. L.sub.1 may include a functional group that is part or all of a NO releasing agent. L.sub.2 may include a functional group that is part or all of a PDE inhibitor. The compound may further include a bond or a biradical that connects L.sub.1 and L.sub.2. The present disclosure further provides a method of treating or preventing a disease using the compound or a composition including the compound.

Provided are a pyranochromenyl phenol derivative, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical composition for preventing or treating metabolic syndrome or inflammatory disease comprising same. The present invention is efficacious in preventing or treating metabolic syndrome or inflammatory disease and is chemically stable.

Provided are a pyranochromenyl phenol derivative, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical composition for preventing or treating metabolic syndrome or inflammatory disease comprising same. The present invention is efficacious in preventing or treating metabolic syndrome or inflammatory disease and is chemically stable.

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of Formula (I) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer's disease, dermatitis, dyslipidemia, cancer and other diseases or disorders.

##STR00001##

A novel compound is provided. A light-emitting element with high emission efficiency and a long lifetime is provided. The compound is an organic compound that includes a benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton (General Formula (G0)). The 2-position of the benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton has a substituent and the 6- to 9-positions of the skeleton have at least one substituent. Any one of the substituents bonded to the 6- to 9-positions is bonded to the benzofuro[3,2-d]pyrimidine or benzothieno[3,2-d]pyrimidine skeleton via a phenylene group. A light-emitting element including the compound is provided.